These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 14502103)

  • 21. The cardiovascular effects of metformin: further reasons to consider an old drug as a cornerstone in the therapy of type 2 diabetes mellitus.
    Anfossi G; Russo I; Bonomo K; Trovati M
    Curr Vasc Pharmacol; 2010 May; 8(3):327-37. PubMed ID: 19485923
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Cardiovascular effects of the thiazolidinedione troglitazone].
    Yamada K; Kuzuya H; Nakano T
    Nihon Rinsho; 2000 Feb; 58(2):435-9. PubMed ID: 10707572
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Characteristic of metformin for treatment of impaired glucose tolerance].
    Ishida W; Satoh J
    Nihon Rinsho; 2005 Feb; 63 Suppl 2():433-7. PubMed ID: 15779418
    [No Abstract]   [Full Text] [Related]  

  • 24. Metformin and vascular protection: a cardiologist's view.
    Libby P
    Diabetes Metab; 2003 Sep; 29(4 Pt 2):6S117-20. PubMed ID: 14502109
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical efficacy of metformin against insulin resistance parameters: sinking the iceberg.
    Zimmet P; Collier G
    Drugs; 1999; 58 Suppl 1():21-8; discussion 75-82. PubMed ID: 10576521
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanisms of action of metformin in type 2 diabetes and associated complications: an overview.
    Correia S; Carvalho C; Santos MS; Seiça R; Oliveira CR; Moreira PI
    Mini Rev Med Chem; 2008 Nov; 8(13):1343-54. PubMed ID: 18991752
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metformin.
    Bell PM; Hadden DR
    Endocrinol Metab Clin North Am; 1997 Sep; 26(3):523-37. PubMed ID: 9314013
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metformin: new understandings, new uses.
    Hundal RS; Inzucchi SE
    Drugs; 2003; 63(18):1879-94. PubMed ID: 12930161
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association between metformin use and below-the-knee arterial calcification score in type 2 diabetic patients.
    Mary A; Hartemann A; Liabeuf S; Aubert CE; Kemel S; Salem JE; Cluzel P; Lenglet A; Massy ZA; Lalau JD; Mentaverri R; Bourron O; Kamel S
    Cardiovasc Diabetol; 2017 Feb; 16(1):24. PubMed ID: 28202017
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Serum level of retinol-binding protein 4 in obese patients with insulin resistance and in patients with type 2 diabetes treated with metformin].
    Tajtáková M; Semanová Z; Ivancová G; Petrovicová J; Donicová V; Zemberová E
    Vnitr Lek; 2007 Sep; 53(9):960-3. PubMed ID: 18019665
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of metformin treatment on VEGF and PAI-1 levels in obese type 2 diabetic patients.
    Ersoy C; Kiyici S; Budak F; Oral B; Guclu M; Duran C; Selimoglu H; Erturk E; Tuncel E; Imamoglu S
    Diabetes Res Clin Pract; 2008 Jul; 81(1):56-60. PubMed ID: 18358555
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Hypoglycemic therapy in heart disease patients with type 2 diabetes mellitus].
    Cosmi F; Cosmi D
    G Ital Cardiol (Rome); 2010 Jun; 11(6):460-6. PubMed ID: 20922871
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiovascular disease prevention in patients with type 2 diabetes: The role of oral anti-diabetic agents.
    Ajjan RA; Grant PJ
    Diab Vasc Dis Res; 2006 Dec; 3(3):147-58. PubMed ID: 17160909
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of oral antihyperglycemic agents in modifying macrovascular risk factors in type 2 diabetes.
    Lebovitz HE
    Diabetes Care; 1999 Apr; 22 Suppl 3():C41-4. PubMed ID: 10189561
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metformin and pioglitazone: Effectively treating insulin resistance.
    Staels B
    Curr Med Res Opin; 2006; 22 Suppl 2():S27-37. PubMed ID: 16914073
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Diabetes drugs and body weight].
    Eriksson J; Laine M
    Duodecim; 2013; 129(1):73-8. PubMed ID: 23431885
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Insulin-sensitizing agents: metformin and thiazolidinedione derivatives].
    Satoh J
    Nihon Rinsho; 2003 Jul; 61(7):1224-9. PubMed ID: 12877089
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of metformin on the incidence of type 2 diabetes mellitus and cardiovascular disease risk factors in overweight and obese subjects--the Carmos study.
    Andreadis EA; Katsanou PM; Georgiopoulos DX; Tsourous GI; Yfanti GK; Gouveri ET; Diamantopoulos EJ
    Exp Clin Endocrinol Diabetes; 2009 Apr; 117(4):175-80. PubMed ID: 19053032
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metformin-like antidiabetic, cardio-protective and non-glycemic effects of naringenin: Molecular and pharmacological insights.
    Nyane NA; Tlaila TB; Malefane TG; Ndwandwe DE; Owira PMO
    Eur J Pharmacol; 2017 May; 803():103-111. PubMed ID: 28322845
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.